Monday, June 5, 2023, Chicago, Illinois, 6:45 AM – 7:45 AM Central Time (7:45 AM – 8:45 AM Eastern Time)

Breakfast with the Investigators: Urothelial Bladder Cancer

A CME Hybrid Symposium Held in Conjunction with the 2023 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast
6:45 AM – 7:45 AM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Matthew D Galsky, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Co-Leader, Bladder Cancer Center of Excellence
Associate Director, Translational Research
The Tisch Cancer Institute
New York, New York

Andrea Necchi, MD
Associate Professor
Vita-Salute San Raffaele University
Head of Genitourinary Medical Oncology
IRCCS San Raffaele Hospital
Milan, Italy


Scott T Tagawa, MD, MS
Professor of Medicine and Urology
Weill Cornell Medicine
Co-Leader, Experimental Therapeutics Program
Meyer Cancer Center
New York, New York



Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Gilead Sciences Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast Buffet
6:45 AM – 7:45 AM — Educational Meeting

MODULE 1: Current and Future Management of Nonmetastatic Urothelial Bladder Cancer (UBC)

  • Selection of patients with high-risk non-muscle-invasive bladder cancer (NMIBC) for pembrolizumab therapy
  • Ongoing Phase III trials investigating the combination of BCG and anti-PD-1/PD-L1 antibodies for BCG-naïve and BCG-unresponsive NMIBC
  • Rates of pathologic complete response and other clinically relevant endpoints achieved in early trials evaluating neoadjuvant anti-PD-1/PD-L1 antibody therapy for resectable muscle-invasive bladder cancer (MIBC)
  • Key efficacy and safety data from the Phase III CheckMate 274 trial comparing nivolumab to placebo after radical surgery for high-risk MIBC
  • Optimal integration of adjuvant nivolumab into clinical practice and identification of appropriate candidates
  • Ongoing Phase III studies evaluating anti-PD-1/PD-L1 antibodies combined with chemotherapy, chemoradiation therapy, other immune checkpoint inhibitors or targeted therapies for patients with MIBC
  • Mechanism of antitumor activity of and early data with the novel intravesical drug delivery system TAR-200
  • Design, eligibility criteria and key endpoints of the Phase II SunRISe-1 study evaluating TAR-200 and cetrelimab, TAR-200 alone or cetrelimab alone for patients with BCG-unresponsive high-risk NMIBC who are ineligible for or decline radical cystectomy; complete response rates reported with TAR-200 monotherapy and cetrelimab monotherapy
  • Ongoing studies of TAR-200 with and without cetrelimab for NMIBC (eg, SunRISe-3) and MIBC (eg, SunRISe-2, SunRISe-4)

MODULE 2: Recent Advances in the Treatment of Metastatic UBC (mUBC)

  • Current role of pembrolizumab as first-line treatment for mUBC; importance of chemotherapy eligibility and PD-L1 status in the selection of patients for this strategy
  • Long-term follow-up from the JAVELIN Bladder 100 trial of maintenance avelumab after front-line chemotherapy for mUBC
  • Biological rationale for the investigation of anti-PD-1/PD-L1 antibodies in combination with novel therapies, such as enfortumab vedotin or erdafitinib, for patients with previously untreated mUBC
  • Efficacy and safety results from cohort K of the EV-103/KEYNOTE-869 study of enfortumab vedotin alone and in combination with pembrolizumab for cisplatin-ineligible patients with previously untreated mUBC
  • Recent FDA approval of enfortumab vedotin/pembrolizumab for patients with locally advanced or metastatic UBC who are not eligible for cisplatin-containing chemotherapy; optimal integration into routine clinical practice
  • Preliminary data with erdafitinib in combination with cetrelimab for patients with previously untreated mUBC with FGFR3 or FGFR2 genetic alterations
  • Long-term outcomes with enfortumab vedotin for patients with progressive mUBC; integration into the treatment paradigm
  • Extended follow-up with erdafitinib for patients with progressive mUBC and FGFR3 or FGFR2 genetic alterations; emerging results from the Phase III THOR study
  • Principal findings with sacituzumab govitecan for patients with progressive mUBC; optimal incorporation into disease management
  • Spectrum, incidence and severity of toxicities with enfortumab vedotin, erdafitinib and sacituzumab govitecan; mitigation and management strategies

MODULE 3: New and Novel Strategies for mUBC

  • Frequency of HER2 expression in mUBC
  • Mechanism of action of the HER2-targeted antibody-drug conjugate disitamab vedotin; available efficacy and safety findings and ongoing evaluation for mUBC
  • Proportion of patients with mUBC in the Phase II DESTINY-PanTumor02 trial of trastuzumab deruxtecan for pretreated HER2-expressing solid tumors; emerging results and clinical implications of this study
  • Biological rationale for the investigation of PARP inhibitors for mUBC; implications of recently reported studies of PARP inhibition (eg, BAYOU, ATLANTIS) for future research and patient care
  • Preliminary data with and ongoing studies of FGFR inhibitors beyond erdafitinib, such as pemigatinib and futibatinib, for mUBC
  • Available data with and ongoing Phase III trials of anti-PD-1/PD-L1 antibodies combined with anti-CTLA-4 antibodies with or without chemotherapy for mUBC
  • Other promising agents and strategies under investigation for mUBC

Target Audience
This activity is intended for medical oncologists, urologists, hematology-oncology fellows and other healthcare providers involved in the treatment of urothelial bladder cancer (UBC).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider available data supporting the use of anti-PD-1 antibody therapy for high-risk non-muscle-invasive bladder cancer (NMIBC) that is unresponsive to BCG, and determine how this strategy can be appropriately integrated into current care.
  • Evaluate the FDA-approved indication for adjuvant anti-PD-1 antibody therapy for patients with high-risk muscle-invasive bladder cancer (MIBC), and consider the current role of this treatment strategy.
  • Review clinical trial evidence with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy in the treatment of newly diagnosed metastatic UBC, and determine the current utility of these agents in clinical practice.
  • Recall pivotal clinical trial findings leading to the FDA approval of novel compounds with unique mechanisms of action for previously treated locally advanced or metastatic UBC, and identify patients for whom these approaches would be appropriate.
  • Appreciate the biologic rationale for combining anti-PD-1/PD-L1 antibodies with other systemic agents with established efficacy in UBC, and assess the current and potential role of these regimens in patient care.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for patients with advanced or metastatic UBC.
  • Develop an understanding of the biologic rationale for, available research findings with and ongoing studies evaluating promising investigational agents and strategies for NMIBC, MIBC and metastatic UBC.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Prof Necchi has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Galsky — Consulting Agreements: AbbVie Inc, Alligator Bioscience, Analog Devices Inc, Asieris Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bicycle Therapeutics, Bristol Myers Squibb, Curis Inc, Dragonfly Therapeutics, EMD Serono Inc, FUJIFILM Pharmaceuticals USA Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Janssen Biotech Inc, Merck, Numab Therapeutics AG, Rappta Therapeutics, Pfizer Inc, Seagen Inc, Silverback Therapeutics, UroGen Pharma; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Dendreon Pharmaceuticals Inc, Genentech, a member of the Roche Group, Merck, Novartis. Dr Tagawa — Consulting Agreements: AbbVie Inc, AIkido Pharma Inc, Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Blue Earth Therapeutics, Clarity Pharmaceuticals, Clovis Oncology, Convergent Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Exact Sciences Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, Merck, Myovant Sciences, Novartis, Pfizer Inc, POINT Biopharma, QED Therapeutics, Sanofi, Seagen Inc, Telix Pharmaceuticals Limited, Tolmar; Contracted Research: AbbVie Inc, Ambrx, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Clovis Oncology, Genentech, a member of the Roche Group, Gilead Sciences Inc, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Karyopharm Therapeutics, Lumos Pharma, Medivation Inc, a Pfizer Company, Merck, Novartis, Ocuphire Pharma Inc, POINT Biopharma, Sanofi, Seagen Inc, Takeda Pharmaceuticals USA Inc; Patent: Gilead Sciences Inc (biomarkers for sacituzumab govitecan therapy); Stock Options/Ownership — Public Company: AIkido Pharma Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Gilead Sciences Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Grand Ballroom (Level 2)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 
This activity is intended for medical and radiation oncologists, urologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of urothelial bladder cancer.

​ There is no fee to participate in this hybrid event. For the in-person symposium in Chicago, preregistration is required as seating is limited.
​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

In-person Registration for clinicians in practice »
 
IN-PERSON registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

In-person Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.